Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2017

Conditions
Glioblastoma
Interventions
DRUG

Cilengitide

2000 mg by vein twice weekly of each 28 day cycle.

DRUG

Bevacizumab

10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.

BEHAVIORAL

Questionnaire

Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brain Tumor Trials Collaborative

OTHER

collaborator

EMD Serono

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01782976 - Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | Biotech Hunter | Biotech Hunter